MedTrace Logo

Cilostazol and Aspirin in Stroke and TIA

NCT06522113 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2024-08-06

No results posted yet for this study

Summary

This study is a randomized, open-labelled trial. We randomly assigned patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with cilostazol and aspirin or to clopidogrel plus aspirin. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis.

Conditions

Interventions

DRUG

Cilostazol

patients were given cilostazol 100mg twice a day with aspirin

DRUG

Clopidogrel

patients were given clopidogrel 75mg with aspirin

Sponsors & Collaborators

  • Incheon St.Mary's Hospital

    lead OTHER

Principal Investigators

  • Taewon Kim, Dr · the catholic university of korea, neurology department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-18
Primary Completion
2022-10-17
Completion
2022-10-17

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06522113 on ClinicalTrials.gov